May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Retinal Vascular Permeability Is Regulated by VEGFR1 and VEGFR2
Author Affiliations & Notes
  • W. Xiao
    Ophthalmology, Johns Hopkins Univ Sch Med, Baltimore, MD
  • S.A. Vinores
    Ophthalmology, Johns Hopkins Univ Sch Med, Baltimore, MD
  • D. Collen
    Thrombogenics Ltd, Leuven, Belgium
  • P. Carmeliet
    Flanders Interuniv Inst for Biotechnology, Center for Transgene Technology & Gene Therapy, Univ Leuven, Belgium
  • P.A. Campochiaro
    Ophthalmology, Johns Hopkins Univ Sch Med, Baltimore, MD
  • Footnotes
    Commercial Relationships  W. Xiao, None; S.A. Vinores, None; D. Collen, None; P. Carmeliet, None; P.A. Campochiaro, None.
  • Footnotes
    Support  Johns Hopkins Univ. Institutional Research Grant, Research to Prevent Blindness (Lew R. Wasserman Merit Award and an unrestricted grant)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 503. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      W. Xiao, S.A. Vinores, D. Collen, P. Carmeliet, P.A. Campochiaro; Retinal Vascular Permeability Is Regulated by VEGFR1 and VEGFR2 . Invest. Ophthalmol. Vis. Sci. 2006;47(13):503.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : VEGF has been thought to promote vascular permeability solely through VEGF receptor–2 (VEGFR2), but recent findings have suggested that VEGFR1 is also implicated. Using highly specific antibodies to VEGFR2 and placental growth factor (PlGF), which binds to VEGFR1, but not VEGFR2, we hope to establish whether both receptor isotypes function in mediating retinal vascular permeability.

Methods: : VEGF transgenic mice (V6) received intraperitoneal (ip) injections of 40µg/g body weight VEGFR2 antibody (Thromb–X, Leuven, Belgium) every 3 days, beginning at postnatal day 5 (P5) and the blood–retinal barrier (BRB) was assessed using 3H–mannitol at P17. Oxygen–induced ischemic retinopathy (OIR) was generated in C57BL/6 mice by incubating them in 75% oxygen from P7–12 and then removing them to the relative hypoxia of room air. Mice with OIR and littermate controls received ip injections of 0.25 or 0.5mg anti–PlGF antibody on P12 and P14 or 40µg/g anti–VEGFR2 antibody (Thromb–X) on P12 and P15 and the BRB was assessed on P17.

Results: : Anti–VEGFR2 antibody suppressed retinal vascular leakage in VEGF transgenic mice (retina/lung leakage ratio [RLLR] decreased 35%; retina/renal leakage ratio [RRLR] decreased 54%; p<0.001) and mice with OIR (RLLR and RRLR decreased 17%; p=0.01). Anti–PlGF antibody at a dosage of 0.5mg, but not lower, suppressed retinal vascular leakage in mice with OIR (RLLR decreased 33%; RRLR decreased 41%; p<0.002).

Conclusions: : The suppression of BRB breakdown by anti–VEGFR2 in VEGF transgenic mice and mice with OIR confirmed that VEGF promotes retinal vascular leakage via VEGFR2. Since anti–PlGF mediated neutralization of PlGF, which binds to VEGFR1, but not VEGFR2, also suppressed BRB breakdown, this provides evidence that VEGFR1 is also implicated in promoting retinal vascular permeability. Therefore, in ocular disorders that upregulate VEGF and/or PlGF, such as diabetic retinopathy or other ischemic retinopathies or age–related macular degeneration, targeting a single VEGF receptor isotype to prevent macular edema may not yield optimal results.

Keywords: growth factors/growth factor receptors • ischemia • transgenics/knock-outs 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.